Rhythm Management in Atrial Fibrillation-With a Prima Therapy: Part 1

PACE - Pacing and Clinical Electrophysiology 21, 590-602

DOI: 10.1111/j.1540-8159.1998.tb00103.x

Citation Report

#	Article	IF	CITATIONS
1	Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. American Journal of Cardiology, 1998, 82, 72N-81N.	1.6	15
2	Atrial Fibrillation: Immediate Evaluation and Management. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 93-95.	1.0	0
3	The Long-term Pharmacologic Management of Atrial Fibrillation for Control of Rate and Rhythm. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 96-99.	1.0	0
4	Current status of calcium channel blockers in patients with cardiovascular disease. Current Problems in Cardiology, 1999, 24, 229-340.	2.4	13
5	ATRIAL FIBRILLATION IN THE ELDERLY. Cardiology Clinics, 1999, 17, 173-188.	2.2	19
6	Association Between Atrial Fibrillation and Appropriate Implantable Cardioverter Defibrillator Therapy: Results from a Prospective Study. Journal of Cardiovascular Electrophysiology, 2000, 11, 1208-1214.	1.7	113
7	Therapy of Atrial Fibrillation: Rhythm Control Versus Rate Control. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 891-903.	1.2	25
8	Drug choices in the treatment of atrial fibrillation. American Journal of Cardiology, 2000, 85, 12-19.	1.6	58
9	Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter. Circulation, 2000, 102, 2385-2390.	1.6	425
10	Antiarrhythmic Agents. Drug Safety, 2000, 23, 509-532.	3.2	96
11	Preload-adjusted maximal power: a novel index of left ventricular contractility in atrial fibrillation. British Heart Journal, 2002, 88, 170-176.	2.1	13
12	Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. British Heart Journal, 2002, 87, 535-543.	2.1	117
13	Intermittent Brugada syndrome misdiagnosed as acute myocardial infarction and unmasked with propafenone. British Heart Journal, 2002, 87, 543-543.	2.1	11
14	Management of Atrial Fibrillation. Critical Pathways in Cardiology, 2002, 1, 3-11.	0.5	0
15	Rate Control in Atrial Fibrillation. Drugs, 2003, 63, 1489-1509.	10.9	39
16	Pharmacological Management of Atrial Fibrillation following Cardiac Surgery. American Journal of Cardiovascular Drugs, 2005, 5, 361-369.	2.2	20
17	Cell Therapy for Rate Control in Atrial Fibrillation. Circulation, 2006, 113, 2474-2476.	1.6	6
18	Adverse Drug Reactions in Patients with Cardiovascular Disease. Current Problems in Cardiology, 2008, 33, 703-768.	2.4	30

## CITATION REPORT

#	Article	IF	CITATIONS
19	Biological Therapies for Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2008, 52, 222-227.	1.9	10
20	Redox Regulation, NF-κB, and Atrial Fibrillation. Antioxidants and Redox Signaling, 2009, 11, 2265-2277.	5.4	69
21	Prognostic Importance of Atrial Fibrillation in Implantable Cardioverter-Defibrillator Patients. Journal of the American College of Cardiology, 2010, 55, 879-885.	2.8	74
22	Biological Therapies for Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2016, 67, 19-25.	1.9	12
23	Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 91-104.	1.3	42
24	A New Beat on an Old Rhythm. American Journal of Nursing, 2000, 100, 42-50.	0.4	1
25	Hybrid pharmacological and ablative therapy for the management of symptomatic atrial fibrillation. Netherlands Heart Journal, 2002, 10, 8-12.	0.8	0
26	Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?. Journal of Atrial Fibrillation, 2008, 1, 21.	0.5	8